● Recruiting

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Condition: Advanced HR+/HER2- Breast Cancer · Advanced CCNE1-amplified Solid Tumors · Metastatic Castration-resistant Prostate Cancer · Sponsor: Novartis Pharmaceuticals

PhasePhase 1/Phase 2

Planned participants205

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

Phase I: Characterize safety and tolerability of GVV858 as a single agent and in combination with fulvestrant or letrozole. Identify dose range for optimization/recommended dose for further clinical evaluation. Phase II: Further characterize the safety and tolerability of GVV858 in combination with fulvestrant in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer.

This description comes directly from the study's public registry record.

Talk to the study team

Novartis Pharmaceuticals · 1-888-669-6682 · novartis.email@novartis.com

Novartis Pharmaceuticals · +41613241111

Always discuss trial participation with your own doctor first.

Locations (14)

Tennessee Oncology PLLC	Nashville, Tennessee, United States	Recruiting
START	San Antonio, Texas, United States	Recruiting
Novartis Investigative Site	Olomouc, Czechia	Recruiting
Novartis Investigative Site	Odense C, Denmark	Recruiting
Novartis Investigative Site	Pierre-Bénite, France	Recruiting
Novartis Investigative Site	Jena, Thuringia, Germany	Recruiting
Novartis Investigative Site	Essen, Germany	Recruiting
Novartis Investigative Site	Milan, MI, Italy	Recruiting
Novartis Investigative Site	Milan, Italy	Recruiting
Novartis Investigative Site	Kyoto, Japan	Recruiting
Novartis Investigative Site	Singapore, Singapore	Recruiting
Novartis Investigative Site	Barcelona, Spain	Recruiting

+ 2 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07288359